vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.

Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $129.5M, roughly 2.0× Arcutis Biotherapeutics, Inc.). On growth, Arcutis Biotherapeutics, Inc. posted the faster year-over-year revenue change (81.5% vs 62.7%). Over the past eight quarters, Arcutis Biotherapeutics, Inc.'s revenue compounded faster (70.1% CAGR vs 46.2%).

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.

ARQT vs PLMR — Head-to-Head

Bigger by revenue
PLMR
PLMR
2.0× larger
PLMR
$253.4M
$129.5M
ARQT
Growing faster (revenue YoY)
ARQT
ARQT
+18.8% gap
ARQT
81.5%
62.7%
PLMR
Faster 2-yr revenue CAGR
ARQT
ARQT
Annualised
ARQT
70.1%
46.2%
PLMR

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
ARQT
ARQT
PLMR
PLMR
Revenue
$129.5M
$253.4M
Net Profit
$17.4M
Gross Margin
91.0%
Operating Margin
14.2%
28.7%
Net Margin
13.4%
Revenue YoY
81.5%
62.7%
Net Profit YoY
EPS (diluted)
$0.13
$2.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
PLMR
PLMR
Q2 26
$129.5M
Q1 26
$105.4M
Q4 25
$129.5M
$253.4M
Q3 25
$99.2M
$244.7M
Q2 25
$81.5M
$203.3M
Q1 25
$65.8M
$174.6M
Q4 24
$71.4M
$155.8M
Q3 24
$44.8M
$148.5M
Net Profit
ARQT
ARQT
PLMR
PLMR
Q2 26
$17.4M
Q1 26
$-11.3M
Q4 25
$17.4M
Q3 25
$7.4M
$51.5M
Q2 25
$-15.9M
$46.5M
Q1 25
$-25.1M
$42.9M
Q4 24
$-10.8M
Q3 24
$-41.5M
$30.5M
Gross Margin
ARQT
ARQT
PLMR
PLMR
Q2 26
91.0%
Q1 26
90.7%
Q4 25
91.0%
Q3 25
91.2%
Q2 25
90.8%
Q1 25
86.6%
Q4 24
90.3%
Q3 24
87.7%
Operating Margin
ARQT
ARQT
PLMR
PLMR
Q2 26
14.2%
Q1 26
-8.6%
Q4 25
14.2%
28.7%
Q3 25
8.6%
27.4%
Q2 25
-17.9%
29.5%
Q1 25
-37.3%
30.8%
Q4 24
-10.7%
28.9%
Q3 24
-87.3%
25.9%
Net Margin
ARQT
ARQT
PLMR
PLMR
Q2 26
13.4%
Q1 26
-10.7%
Q4 25
13.4%
Q3 25
7.5%
21.0%
Q2 25
-19.5%
22.9%
Q1 25
-38.1%
24.6%
Q4 24
-15.1%
Q3 24
-92.8%
20.5%
EPS (diluted)
ARQT
ARQT
PLMR
PLMR
Q2 26
$0.13
Q1 26
$-0.09
Q4 25
$0.14
$2.05
Q3 25
$0.06
$1.87
Q2 25
$-0.13
$1.68
Q1 25
$-0.20
$1.57
Q4 24
$-0.09
$1.29
Q3 24
$-0.33
$1.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
PLMR
PLMR
Cash + ST InvestmentsLiquidity on hand
$42.9M
$106.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$189.5M
$942.7M
Total Assets
$433.0M
$3.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
PLMR
PLMR
Q2 26
$42.9M
Q1 26
$34.8M
Q4 25
$42.9M
$106.9M
Q3 25
$47.1M
$111.7M
Q2 25
$72.7M
$81.3M
Q1 25
$53.1M
$119.3M
Q4 24
$71.3M
$80.4M
Q3 24
$134.9M
$86.5M
Total Debt
ARQT
ARQT
PLMR
PLMR
Q2 26
Q1 26
Q4 25
$109.0M
Q3 25
$108.5M
Q2 25
$108.0M
Q1 25
$107.6M
Q4 24
$107.2M
Q3 24
$204.6M
Stockholders' Equity
ARQT
ARQT
PLMR
PLMR
Q2 26
$189.5M
Q1 26
$189.6M
Q4 25
$189.5M
$942.7M
Q3 25
$158.1M
$878.1M
Q2 25
$139.0M
$847.2M
Q1 25
$142.7M
$790.4M
Q4 24
$157.5M
$729.0M
Q3 24
$156.6M
$703.3M
Total Assets
ARQT
ARQT
PLMR
PLMR
Q2 26
$433.0M
Q1 26
$460.0M
Q4 25
$433.0M
$3.1B
Q3 25
$371.0M
$2.9B
Q2 25
$352.4M
$2.8B
Q1 25
$344.1M
$2.4B
Q4 24
$348.9M
$2.3B
Q3 24
$437.4M
$2.3B
Debt / Equity
ARQT
ARQT
PLMR
PLMR
Q2 26
Q1 26
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
PLMR
PLMR
Operating Cash FlowLast quarter
$409.1M
Free Cash FlowOCF − Capex
$409.0M
FCF MarginFCF / Revenue
161.4%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$700.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
PLMR
PLMR
Q2 26
Q1 26
Q4 25
$26.2M
$409.1M
Q3 25
$-1.8M
$83.6M
Q2 25
$324.0K
$120.9M
Q1 25
$-30.4M
$87.2M
Q4 24
$-748.0K
$261.2M
Q3 24
$-34.7M
$100.3M
Free Cash Flow
ARQT
ARQT
PLMR
PLMR
Q2 26
Q1 26
Q4 25
$409.0M
Q3 25
$83.6M
Q2 25
$246.0K
$120.8M
Q1 25
$-31.0M
$87.1M
Q4 24
$260.9M
Q3 24
$-34.8M
$100.1M
FCF Margin
ARQT
ARQT
PLMR
PLMR
Q2 26
Q1 26
Q4 25
161.4%
Q3 25
34.2%
Q2 25
0.3%
59.4%
Q1 25
-47.1%
49.9%
Q4 24
167.5%
Q3 24
-77.8%
67.4%
Capex Intensity
ARQT
ARQT
PLMR
PLMR
Q2 26
Q1 26
Q4 25
0.0%
0.1%
Q3 25
0.0%
0.0%
Q2 25
0.1%
0.0%
Q1 25
0.9%
0.0%
Q4 24
0.0%
0.2%
Q3 24
0.3%
0.1%
Cash Conversion
ARQT
ARQT
PLMR
PLMR
Q2 26
Q1 26
Q4 25
1.51×
Q3 25
-0.24×
1.63×
Q2 25
2.60×
Q1 25
2.03×
Q4 24
Q3 24
3.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons